01Overview 02Follow the Money 03Daily Brief 04Live 05Congress 06Corporate Insiders 07Government Money 08Political Influence 09Institutions 10Washington Network 11Follow the Power 12Disclosure Clock 13AI Investigator 14Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…

Overview Follow the Money Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

01Overview 02Follow the Money 03Daily Brief 04Live 05Congress 06Corporate Insiders 07Government Money 08Political Influence 09Institutions 10Washington Network 11Follow the Power 12Disclosure Clock 13AI Investigator 14Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

Overview Follow the Money Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

Data sources

SEC FORM 42h ago

HOUSE PTR2h ago

SEC 13F2h ago

ROBINHOOD CHAIN2h ago

Public company

IMMXImmix Biopharma, Inc.

CIK 0001873835

EDGAR filings Open in network

Disclosed transactions0

Buys / sells0 / 0

Max Insider Score—

Connections5with evidence

IMMX · disclosed activity on price

Disclosed transactions

No records

No transactions recorded for this profile.

Verified connections

In industryevidence
Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
← Lobbied forevidence
BROWNSTEIN HYATT FARBER SCHRECK, LLPLDA RR 2026 fourth quarter · Pharmacy, Health issues · Nov 4, 2026
← Lobbied forevidence
AXADVOCACY GOVERNMENT RELATIONSLDA Q2 2026 second quarter · Health issues · Aug 26, 2026
← Lobbied forevidence
CONTINENTAL STRATEGY, LLCLDA Q2 2026 second quarter · MED · Aug 26, 2026
← Lobbied forevidence

TARPLIN, DOWNS & YOUNG, LLC

LDA Q2 2026 second quarter · Health issues · Aug 26, 2026

Lobbying

$215K reported · de-duplicated

2026 Q2 $145K via firms2026 Q4 $0 via firms2026 Q1 $70K via firms

BROWNSTEIN HYATT FARBER SCHRECK, LLP—2026 Q4 · posted Nov 4, 2026 · Pharmacy, Health issues
CONTINENTAL STRATEGY, LLC$50K2026 Q1 · posted Aug 26, 2026 ·
AXADVOCACY GOVERNMENT RELATIONS—2026 Q2 · posted Aug 26, 2026 · Health issues
TARPLIN, DOWNS & YOUNG, LLC$20K2026 Q1 · posted Aug 26, 2026 · Health issues
AXADVOCACY GOVERNMENT RELATIONS$20K2026 Q2 · posted Aug 26, 2026 · Health issues
CONTINENTAL STRATEGY, LLC—2026 Q1 · posted Aug 26, 2026 · MED
CONTINENTAL STRATEGY, LLC$105K2026 Q2 · posted Aug 26, 2026 · MED
TARPLIN, DOWNS & YOUNG, LLC—2026 Q1 · posted Aug 26, 2026 · Health issues
TARPLIN, DOWNS & YOUNG, LLC$20K2026 Q2 · posted Aug 26, 2026 · Health issues

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.